NCT04436978 - What is the Optimal Antithrombotic Strategy in Patients With Atrial Fibrillation Undergoing PCI? | Biotech Hunter

Enrollment

2,000

Participants

Timeline

Start Date

January 11, 2023

Primary Completion Date

October 1, 2027

Study Completion Date

December 1, 2027

Conditions

Acute Coronary SyndromeMyocardial InfarctionAtrial FibrillationAtrial FlutterSTEMI - ST Elevation Myocardial InfarctionNSTEMI - Non-ST Segment Elevation MIBleedingStrokeStent ThrombosisEmbolismCoronary Artery Disease

Interventions

DRUG

30-day DAPT

DAPT (aspirin + P2Y12 inhibitor) during the first 30 days following PCI. After 30 days, all patients will be treated with edoxaban and a P2Y12 inhibitor.

DRUG

Guideline-directed therapy

Guideline-directed therapy (edoxaban + P2Y12 inhibitor, aspirin limited to in-hospital use or up to 30 days in selected high-risk patients)

Trial Locations (20)

Unknown

RECRUITING

ASZ Aalst, Aalst

RECRUITING

UZ Antwerpen, Antwerp

RECRUITING

Imelda Ziekenhuis, Bonheiden

RECRUITING

UZ Brussel, Brussels

RECRUITING

Ziekenhuis Oost-Limburg, Genk

RECRUITING

AZ Maria Middelares Gent, Ghent

NOT_YET_RECRUITING

Jan Yperman, Ieper

RECRUITING

AZ Groeninge, Kortrijk

RECRUITING

UZ Leuven, Leuven

RECRUITING

AZ Delta, Roeselare

RECRUITING

Noordwest Ziekenhuisgroep, Alkmaar

RECRUITING

Amsterdam UMC, Amsterdam

RECRUITING

OLVG, Amsterdam

RECRUITING

Catharina Ziekenhuis, Eindhoven

RECRUITING

Treant Zorggroep, Emmen

NOT_YET_RECRUITING

Zuyderland Ziekenhuis, Heerlen

RECRUITING

Tergooi MC, Hilversum

RECRUITING

St. Antonius Hospital, Nieuwegein

RECRUITING

Hagaziekenhuis, The Hague

RECRUITING

Elisabeth Tweesteden Ziekenhuis, Tilburg